Michael P. Link – författare

T is is the f rst edition of Pediatric Lymphomas. T e ment of both Hodgkin and non-Hodgkin lymphomas, editors have been colleagues for more than 25 years and lymphoproliferative disorders associated with - and have been involved in the design and coordination munodef ciency. In addition, three chapters focus on of clinical trials and multimodality approaches for the pathology, molecular biology, and genetics of children with Hodgkin and non-Hodgkin lymphomas. Hodgkin and non-Hodgkin lymphoma including the Progress in elucidating the pathogenesis and in the di- rare cutaneous lymphomas. We hope that Pediatric agnosis and treatment of lymphomas in children has Lymphomas will be a useful resource for practitioners been one of the great success stories in pediatric oncol- from the many dif erent disciplines involved in the ogy. Prior to 1970, fewer than 20% of children with comprehensive care of children with lymphomas. malignant lymphomas survived. Today, more than T e authors are all leading experts in the area of 90% of children diagnosed with Hodgkin lymphoma childhood lymphomas. We wish to thank them for all survive and more than 80% of children with non- of the time and ef ort that went into their contribu- Hodgkin lymphoma are considered cured. Continued tions. If this f rst edition is helpful to our diverse re- improvement in survival has occurred as the result of ership, it is because of the authors.

T is is the f rst edition of Pediatric Lymphomas. T e ment of both Hodgkin and non-Hodgkin lymphomas, editors have been colleagues for more than 25 years and lymphoproliferative disorders associated with - and have been involved in the design and coordination munodef ciency. In addition, three chapters focus on of clinical trials and multimodality approaches for the pathology, molecular biology, and genetics of children with Hodgkin and non-Hodgkin lymphomas. Hodgkin and non-Hodgkin lymphoma including the Progress in elucidating the pathogenesis and in the di- rare cutaneous lymphomas. We hope that Pediatric agnosis and treatment of lymphomas in children has Lymphomas will be a useful resource for practitioners been one of the great success stories in pediatric oncol- from the many dif erent disciplines involved in the ogy. Prior to 1970, fewer than 20% of children with comprehensive care of children with lymphomas. malignant lymphomas survived. Today, more than T e authors are all leading experts in the area of 90% of children diagnosed with Hodgkin lymphoma childhood lymphomas. We wish to thank them for all survive and more than 80% of children with non- of the time and ef ort that went into their contribu- Hodgkin lymphoma are considered cured. Continued tions. If this f rst edition is helpful to our diverse re- improvement in survival has occurred as the result of ership, it is because of the authors.